Seer, Inc.

NASDAQ:SEER

Biotechnology

Healthcare
$1.44 +0.29%

+$0.01 today

Market cap
$80.37M
Beta
1.59
P/E (TTM)
-1.4
EPS (TTM)
-$1.26
52W Low $1.65High $2.41

Volume 0.23M

Average 0.32M

SEER Investing Cash Flow

Net cash used in or generated by investments in assets, acquisitions, and securities.

Seer, Inc.NASDAQ: SEER

Investing Cash Flow · Q1 FY2026 · quarter ended Mar 2026

Investing cash flow declines year over year

Q1 FY2026 investing cash flow of $18.08M fell 26.6% year over year, behind the -5.3% change in trailing-twelve-month investing cash flow. Sequentially, it rose 39.3% from the prior quarter.

Context

  • Investing cash flow amounted to 381.8% of revenue in FY2025, down 90.4 pp from a year earlier.
  • Investing cash flow increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from -26.6% toward the trailing-twelve-month pace of -5.3%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$18.08M+39.3% QoQ
Last fiscal yearDec 2025
$61.55M-6.5% YoY
LTMMar 2026
$55.01M-5.3% YoY
Investing Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-26.6%——
1 year-6.5%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Investing Cash Flow history

USD · from the cash flow

Latest · FY2025
61.55M USD
Year-over-year change
-6.5%

Investing Cash Flow vs competitors

How SEER compares with its peers on the latest reported figures

  • Peers report in different currencies, so investing cash flow is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -5.3% is the 8th highest of 19, against a peer median of -52.8%.
  • Investing cash flow amounts to 365.8% of revenue for SEER, versus a peer median of 230.0%.
SEER Competitors
Investing Cash Flow for SEER and competitors
Company Period LTM YoY 3-year CAGR% of revenue
KYMRKymera Therapeutics, Inc.LTM Jun 2026$752.49M USD-3954.2%—716.7%
MLYSMineralys Therapeutics, Inc.LTM Jun 2026$484.16M USD-1865.8%+161.6%—
GLUEMonte Rosa Therapeutics, Inc.LTM Mar 2026$262.6M USD+69.9%-22.6%611.4%
ORICORIC Pharmaceuticals, Inc.LTM Mar 2026$188.46M USD-277.0%+10.7%—
CGEMCullinan Therapeutics, Inc.LTM Mar 2026$175.6M USD+256.1%-10.3%—
FHTXFoghorn Therapeutics Inc.LTM Mar 2026$64.92M USD+335.2%—230.0%
NKTXNkarta, Inc.LTM Mar 2026$61.9M USD+164.0%——
SEERSeer, Inc.LTM Mar 2026$55.01M USD-5.3%—365.8%
QSIQuantum-Si incorporatedLTM Mar 2026$46.13M USD+589.6%—2490.6%
MOLNMolecular Partners AGLTM Mar 2026CHF 40.11M CHF-30.7%——
PEPGPepGen Inc.LTM Mar 2026$33.84M USD+266.8%+59.5%—
ANTXAN2 Therapeutics, Inc.LTM Mar 2026$27.41M USD-26.9%——
CCCCC4 Therapeutics, Inc.LTM Mar 2026$21.57M USD-169.0%—61.9%
SANASana Biotechnology, Inc.LTM Mar 2026$7.4M USD-106.7%——
LYELLyell Immunopharma, Inc.LTM Mar 2026$2.01M USD-98.8%—6480.6%
NRIXNurix Therapeutics, Inc.LTM Aug 2026$1.1M USD-83.6%+75.8%0.2%
STTKShattuck Labs, Inc.LTM Mar 2026$361K USD-99.1%—36.1%
PHVSPharvaris N.V.LTM Sep 2026€81.4K EUR-74.9%+9.8%—
MNOVMediciNova, Inc.LTM Mar 2026$13.72K USD+1869.0%-95.8%2.3%
Peer median (excluding SEER) —-52.8%+10.2%230.0%

Competitors are the stored peer set for SEER. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(71.17M)(92.97M)(86.28M)(86.6M)(73.6M)
Depreciation & Amortization2.56M3.94M5.58M6.18M7.25M
Deferred Income Tax1.2M0000
Stock-Based Compensation25.93M33.67M34.42M28.21M15.41M
Change in Working Capital(5.87M)(7.09M)(2.72M)(144K)(579K)
Accounts Receivables(2.5M)(2.87M)302K487K277K
Inventory(3.59M)(1.59M)(1.95M)(2.67M)(2.9M)
Accounts Payables1.6M(1.55M)(987K)3.36M1.06M
Other Working Capital(1.38M)(1.07M)(91K)(1.32M)983K
Other Non-Cash Items1.01M1.66M(10.07M)6.25M7.07M
Operating Cash Flow(46.35M)(60.78M)(59.07M)(46.11M)(44.45M)
Capital Expenditures(6.92M)(10.27M)(7.31M)(3.58M)(1.8M)
Acquisitions (Net)163.96M0000
Purchases of Investments(279.96M)(366.27M)(403.09M)(272.93M)(173.17M)
Sales of Investments116M253.65M448.31M342.03M237.81M
Other Investing Activities(163.96M)170K0343K(1.3M)
Investing Cash Flow(170.88M)(122.72M)37.9M65.86M61.55M
Debt Repayment00000
Common Stock Issued102.96M000458K
Common Stock Repurchased(35K)(20K)(13K)(11.82M)(10.2M)
Dividends Paid00000
Other Financing Activities13.71M3.91M465K321K(827K)
Financing Cash Flow116.63M3.89M452K(11.5M)(10.57M)
Effect of Forex Changes00000
Net Change in Cash(100.59M)(179.61M)(20.71M)8.25M6.53M
Free Cash Flow(53.27M)(71.05M)(66.37M)(49.69M)(46.25M)

Seer, Inc.

NASDAQ:SEER

Intrinsic Alpha fair value

Locked

Current Price

$1.44

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.